227 related articles for article (PubMed ID: 29729100)
1. Immune-related Adverse Events in Cancer Patients.
Pallin DJ; Baugh CW; Postow MA; Caterino JM; Erickson TB; Lyman GH
Acad Emerg Med; 2018 Jul; 25(7):819-827. PubMed ID: 29729100
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
4. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
7. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
[TBL] [Abstract][Full Text] [Related]
8. Hypothalamic expression of PD-L1: does it mediate hypothalamitis?
Iervasi E; Strangio A; Saverino D
Cell Mol Immunol; 2019 Jun; 16(6):625-626. PubMed ID: 30979971
[No Abstract] [Full Text] [Related]
9. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
Lewis AL; Chaft J; Girotra M; Fischer GW
Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
[TBL] [Abstract][Full Text] [Related]
12. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Postow MA; Sidlow R; Hellmann MD
N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
[No Abstract] [Full Text] [Related]
13. Neurological complications of cancer immunotherapy.
Roth P; Winklhofer S; Müller AMS; Dummer R; Mair MJ; Gramatzki D; Le Rhun E; Manz MG; Weller M; Preusser M
Cancer Treat Rev; 2021 Jun; 97():102189. PubMed ID: 33872978
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
15. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
[No Abstract] [Full Text] [Related]
16. Cancer immunotherapy-associated hypophysitis.
Castillero F; Castillo-Fernández O; Jiménez-Jiménez G; Fallas-Ramírez J; Peralta-Álvarez MP; Arrieta O
Future Oncol; 2019 Sep; 15(27):3159-3169. PubMed ID: 31423850
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
18. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
